APOE and Alzheimer disease: Another possible explanation for the ApoE4 difference is that NACC has a more clinically heterogeneous population, including participants with early stages of other diseases for which ApoE4 can be a risk factor, such as Lewy body and vascular dementia, and which can be clinically indistinguishable from AD at CN and MCI stages.